AVRO - AVROバイオ (AVROBIO Inc.) AVROバイオ

 AVROのチャート


 AVROの企業情報

symbol AVRO
会社名 AVROBIO Inc (AVROバイオ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 AVROBIO Inc. is a clinical stage gene therapy company. The Company is focused on developing curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. Its gene therapies employ hematopoietic stem cells that are extracted from the patient and then modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. Its product pipeline includes AVR-RD-01 AVR-RD-02 AVR-RD-03 and AVR-RD-04. The Company is developing AVR-RD-01 for the treatment of Fabry disease. AVR-RD-02 is the Company’s gene therapy for Gaucher disease. AVR-RD-03 is being developed for the treatment of Pompe disease. The Company is developing AVR-RD-04 for the treatment of patients with cystinosis.   AVROバイオは米国のバイオ医薬品企業。臨床段階で、主に希少疾患に対する遺伝子治療に焦点を当てた医薬品の開発・商業化に従事する。同社はリソソ―ム蓄積症に対する幹細胞遺伝子治療を開発し、一度の投与で効果を表す医薬品を手がける。パイプラインにはゴ―シェ病、ポンペ病、シスキシン症の治療薬を含む。本社所在地はマサチュ―セッツ州ケンブリッジ。   AVROBIO's vision is to bring personalized gene therapy to the world. The company aims to prevent, halt or reverse disease throughout the body with a single dose of gene therapy designed to drive durable expression of therapeutic protein, even in hard-to-reach tissues and organs including brain, muscle and bone. Its ex vivo lentiviral gene therapy pipeline includes clinical programs in Fabry disease, Gaucher disease type 1 and cystinosis, as well as preclinical programs in Hunter syndrome, Gaucher disease type 3 and Pompe disease. AVROBIO is powered by its industry leading plato® gene therapy platform, its foundation designed to deliver gene therapy worldwide. The company is headquartered in Cambridge, Mass., with an office in Toronto, Ontario.
本社所在地 One Kendall Square Building 300 Suite 201 Cambridge MA 02139 USA
代表者氏名 Bruce Booth ブルースブース
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 781-962-6030
設立年月日 42309
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 34人
url www.avrobio.com
nasdaq_url https://www.nasdaq.com/symbol/avro
adr_tso
EBITDA EBITDA(百万ドル) -31.03900
終値(lastsale) 25.6
時価総額(marketcap) 612783052.8
時価総額 時価総額(百万ドル) 578.31400
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 423.29900
当期純利益 当期純利益(百万ドル) -35.06700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Avrobio Inc revenues was not reported. Net loss applicable to common stockholders increased from $4.7M to $21M. Higher net loss reflects Research and developme increase from $3.3M to $12.9M (expense) General and administrative increase from $1.2M to $3.9M (expense) Gains/Losses on Trading Derivatives increase from $35K to $1.6M (expense).

 AVROのテクニカル分析


 AVROのニュース

   AVROBIO EPS misses by $0.08  2021/08/05 11:48:56 Seeking Alpha
   Questexs Fierce Life Sciences Clinical Quality Oversight Forum is the First Post-Pandemic In-Person Event for the Clinical Research Community  2021/08/03 17:00:00 Intrado Digital Media
The Annual Gathering features Expert Speakers from Astellas, Merck, Roche/Genentech, Avrobio, Clovis Oncology, Boston Scientific, Bill & Melinda Gates MRI and More The Annual Gathering features Expert Speakers from Astellas, Merck, Roche/Genentech, Avrobio, Clovis Oncology, Boston Scientific, Bill & Melinda Gates MRI and More
   AVROBIO to Present at Two Upcoming Investor Conferences in August  2021/08/02 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming investor conferences: BTIG Virtual Biotechnology Conference 2021 Date: Monday, Aug. 9, 2021 Time: 3:30 p.m. ET 2021 Wedbush PacGrow Healthcare Virtual Conference Panel: Miss Con-GENE-iality - Updates in Gene Tx Date: W
   AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  2021/07/08 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 14,500 shares of the companys common stock to two new employees as inducement awards under the companys 2019 Inducement Plan. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4). The sto
   AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - June 04, 2021  2021/06/04 00:00:00 BioSpace
AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced that the company has granted a non-statutory stock option for the purchase of up to an aggregate of 8,250 shares of the companys common stock to one new employee as an inducement award under the companys 2019 Inducement Plan.
   AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  2021/07/08 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 14,500 shares of the companys common stock to two new employees as inducement awards under the companys 2019 Inducement Plan. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4). The sto
   AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - June 04, 2021  2021/06/04 00:00:00 BioSpace
AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced that the company has granted a non-statutory stock option for the purchase of up to an aggregate of 8,250 shares of the companys common stock to one new employee as an inducement award under the companys 2019 Inducement Plan.
   AVROBIO initiated buy at Needham; estimates more than $2 billion peak sales from pipeline  2021/05/27 18:21:04 Seeking Alpha
   Avrobio (AVRO) Receives a Hold from Leerink Partners  2021/05/18 08:19:26 Smarter Analyst
Leerink Partners analyst Mani Foroohar reiterated a Hold rating on Avrobio (AVRO) on May 13 and set a price target of $10.00. The post Avrobio (AVRO) Receives a Hold from Leerink Partners appeared first on Smarter Analyst .
   Mizuho Securities Thinks Avrobios Stock is Going to Recover  2021/05/14 08:15:57 Smarter Analyst
Mizuho Securities analyst Difei Yang maintained a Buy rating on Avrobio (AVRO) today and set a price target of $28.00. The post Mizuho Securities Thinks Avrobios Stock is Going to Recover appeared first on Smarter Analyst .
   Mid-Afternoon Market Update: Crude Oil Rises 1.5%; AVROBIO Shares Plummet  2021/05/03 14:40:00 Benzinga
Toward the end of trading Monday, the Dow traded up 0.82% to 34,152.49 while the NASDAQ fell 0.36% to 13,912.07. The S&P also rose, gaining 0.41% to …
   Avrobio Plans Registration Trial With Kidney Biopsy Endpoint To Support Potential Full Approval Of Fabry Disease Gene Therapy  2021/05/03 13:42:25 Benzinga
Avrobio Inc (NASDAQ: AVRO ) has provided an update on its regulatory plans for AVR-RD-01, its lentiviral gene therapy for Fabry disease, currently in FAB-GT Phase 2 trial . In March, the FDA granted full approval to Sanofi's SA (NASDAQ: SNY ) Fabrazyme (agalsidase beta) after it received accelerated … Full story available on Benzinga.com
   AVROBIO Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update  2021/03/18 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the fourth quarter and year ended Dec. 31, 2020 and provided a business update. “It has been a highly productive period for AVROBIO, with strong new data updates across all our clinical programs, underscoring the transformative potential of our ex vivo lentiviral gene therapies. Most
   AVROBIO Earnings Report: Here’s what to expect from Stock market Insights & financial analysis  2021/03/15 17:51:00 Stock Market Daily
AVROBIO announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   AVROBIO Receives Orphan Drug Designation from the European Commission for AVR‑RD‑04, an Investigational Gene Therapy for Cystinosis  2021/03/01 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has granted orphan drug designation for AVR-RD-04, the company’s investigational gene therapy for the treatment of cystinosis. AVR-RD-04 consists of the patient’s own hematopoietic stem cells, genetically modified to express cystinosin, the protein that is deficient in pa

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 AVROバイオ AVRO AVROBIO Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)